Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 12, 2008, Pages 1194-1204

  Akhtar, Muhammad A ^a   Mathieson, Kathleen ^a   Arey, Brian ^a   Post, John ^a   Prevette, Renee ^a   Hillier, Amy ^a   Patel, Prahladbhai ^a   Ram, Lakshmi Jaya ^a   Van Thiel, David H ^b   Nadir, Abdul ^a  

^a MARICOPA MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiretroviral medications; Hepatotoxicity; HIV

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIPODYSTROPHY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SIDE EFFECT; VIRUS HEPATITIS;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; CROSS-SECTIONAL STUDIES; FATTY LIVER; HEPATITIS, TOXIC; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 56749168891     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328305b9e0     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
3. Sulkowski MS. Hepatitis C virus and HIV co-infection: a sleeping giant wakes. Hopkins HIV Rep 1999; 11:10-12.
4. Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDS 2005; 19:356-365.
5. Tien PC, Grunfeld C. The fatty liver in AIDS. Semin Gastrointest Dis 2002; 13:47-54.
6. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001; 98:12671-12676.
7. Maida I, Nunez M, Rios MJ, Martin-Carbonero L, Sotgiu G, Toro C, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42:177-182.
8. Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, Pol S. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. Aids 2007; 21:187-192.
9. Arey B, Markov M, Ravi J, Prevette E, Batts K, Nadir A. Nodular regenerative hyperplasia of liver as a consequence of ART. Aids 2007; 21:1066-1068.
10. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. Aids 1998; 12:116-117.
11. Ellozy S, Massen R, Chao L, Divino CM. Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature. Am Surg 2001; 67:680-683.
12. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003; 23:183-194.
13. Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS 2003; 14:776-781.
14. Bollepalli S, Mathieson K, Bay C, Hillier A, Post J, Van Thiel DH, Nadir A. Prevalence of Risk Factors for Hepatitis C Virus in HIV-infected and HIV/Hepatitis C Virus-Coinfected Patients. Sex Transm Dis 2006; 34:367-370.
15. Searle J LBA, Crawford DHG, Powell LW. Iron storage diseases. In: MacSween RN, editor. Pathology of the liver (text book). 4th ed. London: Churchill Livingstone; 2002. pp. 257-272.
16. Lefkowitch JH. Hepatobiliary pathology. Curr Opin Gastroenterol 2006; 22:198-208.
17. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31:162-166.
18. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-820.
19. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276:37514-37519.
20. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
21. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002; 35:1219-1230.
22. McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. Aids 2005; 19:15-23.
23. Eholie SP, Lacombe K, Serfaty L, Wendum D, Girard PM. Acute hepatic cytolysis in an HIV-infected patient taking atazanavir. Aids 2004; 18:1610-1611.
24. Julg B, Bogner JR, Goebel FD. Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report. Aids 2006; 20:1563.
25. Verucchi G, Calza L, Manfredi R, Chiodo F. Incidence of liver toxicity in hiv-infected patients receiving isolated dual nucleoside analogue antitretroviral therapy. J Acquir Immune Defic Syndr 2003; 33:546-548.
26. Batisse D, Van Huyen JP, Piketty C, Canali GG, Karmochkine M, Weiss L, et al. Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues. Aids 2002; 16:2370-2371.
27. Gordon SC, Reddy KR, Gould EE, McFadden R, O'Brien C, De Medina M, et al. The spectrum of liver disease in the acquired immunodeficiency syndrome. J Hepatol 1986; 2:475-484.
28. Bach N, Theise ND, Schaffner F. Hepatic histopathology in the acquired immunodeficiency syndrome. Semin Liver Dis 1992; 12:205-212.
29. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998; 114:842-845.